Dr. Mani Foroohar has joined Leerink Partners’ research team as a managing director and senior research analyst covering therapeutics stocks.
Dr. Foroohar joined Leerink from Aptigon Capital, a Citadel company, where he most recently was a therapeutics analyst focused on U.S. and EU biotechnology, major pharmaceuticals and specialty pharmaceuticals sectors.
Prior to Aptigon, he was an analyst at Green Owl Capital Management and an assistant VP of equity research at Barclays. In 2013, Dr. Foroohar co-founded Cellanyx Diagnostics, a company developing a proprietary live tumor cell, phenotypic platform for precision risk stratification in cancer to inform clinical treatment decision-making.
In a statement, John Sullivan, director of equity research at Leerink, said Dr. Foroohar will cover the growing number of companies developing breakthrough technologies addressing the genetic basis of human disease.
“These companies are among the most exciting, volatile and complex in the industry, and Mani’s combined medical training and buy-side experience should make him a very effective resource for Leerink’s buy-side clients,” he added.